Niranjan Kanesa-Thasan - 04 Jan 2023 Form 4 Insider Report for Icosavax, Inc.

Role
Chief Medical Officer
Signature
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
04 Jan 2023
Net transactions value
-$1,421,162
Form type
4
Filing time
05 Jan 2024, 19:18:38 UTC
Previous filing
14 Nov 2022
Next filing
15 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Options Exercise $11,597 +13,806 +6.2% $0.8400* 237,786 04 Jan 2023 Direct
transaction ICVX Common Stock Options Exercise $77,634 +74,648 +31% $1.04* 312,434 04 Jan 2023 Direct
transaction ICVX Common Stock Options Exercise $70,487 +11,947 +3.8% $5.90 324,381 04 Jan 2023 Direct
transaction ICVX Common Stock Options Exercise $89,580 +5,972 +1.8% $15.00 330,353 04 Jan 2023 Direct
transaction ICVX Common Stock Sale $1,670,460 -106,373 -32% $15.70 223,980 04 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -13,806 -85% $0.000000 2,511 04 Jan 2023 Common Stock 13,806 $0.8400 Direct F2
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -74,648 -64% $0.000000 42,193 04 Jan 2023 Common Stock 74,648 $1.04 Direct F3
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -11,947 -9.9% $0.000000 108,369 04 Jan 2023 Common Stock 11,947 $5.90 Direct F4
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -5,972 -4.8% $0.000000 118,528 04 Jan 2023 Common Stock 5,972 $15.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.70 to $15.78. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 25% of the shares subject to the option vested on April 1, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.
F3 25% of the shares subject to the option vested on January 14, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.
F4 25% of the shares subject to the option vested on March 19, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.
F5 1/48th of the shares subject to the option vest monthly following July 28, 2021, the vesting commencement date.